XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc., trading under the ticker XYN, is a clinical-stage biopharmaceutical company focused on oncology drug development that filed a Form 10-Q with the SEC on November 14, 2017, bearing accession number 0001213900-17-012081. The company operates in the pharmaceutical and life sciences sector, targeting cancer therapeutics as its primary area of clinical focus. The November 2017 quarterly filing reflects the company's reporting obligations during its early post-public-market phase, a period when many biopharmaceutical entities in the SPAC ecosystem were advancing pipeline assets toward clinical milestones. Sign up on SpacDesk for full filing history, entity-level data, and real-time tracking on XYN and hundreds of comparable SPAC-affiliated companies.